More M&A in Biotech Sector - Roche to acquire Promedior!, page-45

Hi Ahjay,

If you read my post, I didn’t imply that Imugene were selling now & that we are in the midst of a Ph2 plus other trials. But how do any of us know what will come along in the near future with novel therapies in Oncology? I wouldn’t be underestimating the potential here for M&A.

This was just an example of the massive potential in M&A in oncology with only one drug in a rare genetic mutation licensed & approved by FDA. Herceptin has fallen off the patent cliff with biosimilar now approved & there will be more MABs to follow. Big Pharma will be filling those gaps.